Merged with Globus Medical in Sep 2023
NUVA - NuVasive, Inc.
NASDAQ
->
Healthcare
->
Medical Devices
San Diego,
United States
Type: Equity
NUVA price evolution
NUVA
| (in millions $) | 30 Jun 2023 | 31 Mar 2023 | 31 Jan 2023 | 30 Sep 2022 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $82.21 | $182.69 | $250.16 | $238.99 |
| Short term investments | ||||
| Net receivables | $267.11 | $250.02 | $249.37 | $235.58 |
| Inventory | $350.81 | $345.94 | $338.6 | $341 |
| Total current assets | $728.25 | $806.36 | $865.21 | $843.23 |
| Long term investments | ||||
| Property, plant & equipment | $452.59 | $448.75 | $441.62 | $433.16 |
| Goodwill & intangible assets | $808.28 | $813.03 | $823.95 | $812.42 |
| Total noncurrent assets | $1361.3 | $1360.8 | $1359.29 | $1331.71 |
| Total investments | ||||
| Total assets | $2089.55 | $2167.15 | $2224.51 | $2174.95 |
| Current liabilities | ||||
| Accounts payable | $118.81 | $122.28 | $120.33 | $119.3 |
| Deferred revenue | ||||
| Short long term debt | $360.79 | $459.41 | $458.07 | $456.92 |
| Total current liabilities | $582.58 | $674.8 | $716.05 | $697.4 |
| Long term debt | $545.36 | $546.48 | $445.07 | $548.26 |
| Total noncurrent liabilities | $614.43 | $618.68 | $639.57 | $645.39 |
| Total debt | $906.15 | $1005.89 | $1006.08 | $1005.18 |
| Total liabilities | $1197.01 | $1293.47 | $1355.62 | $1342.8 |
| Shareholders' equity | ||||
| Retained earnings | $92.47 | $85.1 | $86.11 | $62.04 |
| Other shareholder equity | -$1.26 | -$1.39 | -$3.25 | -$4.36 |
| Total shareholder equity | $892.54 | $873.68 | $868.89 | $832.15 |
| (in millions $) | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $250.16 | $247.59 | $858.36 | $214.53 |
| Short term investments | $173.15 | |||
| Net receivables | $249.37 | $214.4 | $207.07 | $211.53 |
| Inventory | $338.6 | $315.85 | $300.62 | $312.42 |
| Total current assets | $865.21 | $802.42 | $1562.18 | $764.34 |
| Long term investments | ||||
| Property, plant & equipment | $441.62 | $406.65 | $388.64 | $333.25 |
| Goodwill & intangible assets | $823.95 | $876.14 | $711.82 | $762.16 |
| Total noncurrent assets | $1359.29 | $1351.65 | $1130.9 | $1120.95 |
| Total investments | $173.15 | |||
| Total assets | $2224.51 | $2154.07 | $2693.08 | $1885.29 |
| Current liabilities | ||||
| Accounts payable | $20.32 | $115.61 | $110.4 | $97.16 |
| Deferred revenue | ||||
| Short long term debt | $458.07 | $9.87 | $653.18 | $5.57 |
| Total current liabilities | $716.05 | $200.89 | $836.36 | $206.92 |
| Long term debt | $445.07 | $996.58 | $877.86 | $696.45 |
| Total noncurrent liabilities | $639.57 | $1157.98 | $937.8 | $763.17 |
| Total debt | $1006.08 | $1006.44 | $1531.04 | $702.02 |
| Total liabilities | $1355.62 | $1358.87 | $1774.16 | $970.08 |
| Shareholders' equity | ||||
| Retained earnings | $86.11 | $45.71 | $45.32 | $82.47 |
| Other shareholder equity | -$3.25 | -$7.79 | -$7.58 | -$9.42 |
| Total shareholder equity | $868.89 | $795.21 | $918.92 | $915.21 |
| (in millions $) | 30 Jun 2023 | 31 Mar 2023 | 31 Dec 2022 | 30 Sep 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $317.79 | $307.71 | $305.45 | $295.28 |
| Cost of revenue | $89.47 | $86.37 | $90.78 | $80.87 |
| Gross Profit | $228.31 | $221.34 | $214.67 | $214.41 |
| Operating activities | ||||
| Research & development | $28.65 | $24.57 | $25.59 | $23.67 |
| Selling, general & administrative | $163.86 | $176.19 | $159.11 | $154 |
| Total operating expenses | $210.35 | $214.18 | $198 | $192.64 |
| Operating income | $17.96 | $7.17 | $16.67 | $21.77 |
| Income from continuing operations | ||||
| EBIT | $18.49 | $4.56 | $36.34 | $1.54 |
| Income tax expense | $5.12 | $1.19 | $7.92 | -$0.84 |
| Interest expense | $6.01 | $4.38 | $4.34 | $4.35 |
| Net income | ||||
| Net income | $7.36 | -$1.01 | $24.08 | -$1.98 |
| Income (for common shares) | $7.36 | -$1.01 | $24.08 | -$1.98 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1201.94 | $1138.99 | $1050.58 | $1168.07 |
| Cost of revenue | $336.51 | $322.28 | $321.63 | $312.36 |
| Gross Profit | $865.43 | $816.71 | $728.95 | $855.71 |
| Operating activities | ||||
| Research & development | $98.52 | $92.63 | $79.84 | $72.38 |
| Selling, general & administrative | $634.1 | $610.09 | $547.2 | $611.18 |
| Total operating expenses | $782 | $828.74 | $690.65 | $732.66 |
| Operating income | $83.44 | -$12.03 | $38.3 | $123.05 |
| Income from continuing operations | ||||
| EBIT | $69.75 | -$37.33 | $22.92 | $119.04 |
| Income tax expense | $11.91 | $5.7 | -$10.39 | $15.28 |
| Interest expense | $17.42 | $21.06 | $70.47 | $38.52 |
| Net income | ||||
| Net income | $40.41 | -$64.09 | -$37.15 | $65.23 |
| Income (for common shares) | $40.41 | -$64.09 | -$37.15 | $65.23 |
| (in millions $) | 30 Jun 2023 | 31 Mar 2023 | 31 Dec 2022 | 30 Sep 2022 |
|---|---|---|---|---|
| Net income | $7.36 | -$1.01 | $24.08 | -$1.98 |
| Operating activities | ||||
| Depreciation | $32.92 | $33.47 | $36.83 | $36.91 |
| Business acquisitions & disposals | -$3.08 | -$8.67 | -$1.15 | |
| Stock-based compensation | $7.95 | $6.91 | $9.46 | $4.82 |
| Total cash flows from operations | $36.52 | $1.97 | $46.77 | $54.26 |
| Investing activities | ||||
| Capital expenditures | -$34.01 | -$35.15 | -$32.11 | -$38.38 |
| Investments | ||||
| Total cash flows from investing | -$40.09 | -$35.15 | -$40.98 | -$39.52 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $3.42 | -$2.96 | $2.1 | -$0.12 |
| Net borrowings | -$100 | |||
| Total cash flows from financing | -$96.8 | -$34.9 | $1.58 | -$0.5 |
| Effect of exchange rate | -$0.1 | $0.62 | $3.79 | -$2.72 |
| Change in cash and equivalents | -$100.48 | -$67.46 | $11.16 | $11.52 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Net income | $40.41 | -$64.09 | -$37.15 | $65.23 |
| Operating activities | ||||
| Depreciation | $147.03 | $149.52 | $140.94 | $135.59 |
| Business acquisitions & disposals | -$15.07 | -$195.81 | -$4.1 | |
| Stock-based compensation | $28.6 | $25.29 | $18.14 | $30.3 |
| Total cash flows from operations | $169.12 | $182.17 | $185.91 | $235.29 |
| Investing activities | ||||
| Capital expenditures | -$139.23 | -$111.11 | -$105.73 | -$122.88 |
| Investments | $173.02 | -$172.34 | ||
| Total cash flows from investing | -$155.19 | -$136.06 | -$281.93 | -$134.48 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.14 | -$2.6 | $19.42 | -$8.06 |
| Net borrowings | -$649.43 | $873.85 | ||
| Total cash flows from financing | -$8.59 | -$653.35 | $736.66 | -$6.64 |
| Effect of exchange rate | -$2.76 | -$3.54 | $3.2 | $0.13 |
| Change in cash and equivalents | $2.57 | -$610.78 | $643.84 | $94.29 |
News
|
Should You Investigate NuVasive, Inc. (NASDAQ:NUVA) At US$39.75?
Simply Wall St. via Yahoo Finance
5 Sep 2023
|
|
NuVasive (NUVA) Q2 Earnings Meet Estimates, Margins Down
Zacks via Yahoo Finance
4 Aug 2023
|
|
Here's Why You Should Retain Globus Medical (GMED) Stock Now
Zacks via Yahoo Finance
17 Jul 2023
|
|
NuVasive (NUVA) Q1 Earnings Beat Estimates, Margins Fall
Zacks via Yahoo Finance
11 May 2023
|
|
Globus Medical (GMED) Q1 Earnings Beat, Operating Margin Dips
Zacks via Yahoo Finance
5 May 2023
|
|
Globus Medical Stock: Still Attractive After NuVasive Selloff (NYSE:GMED)
Seeking Alpha
4 May 2023
|
|
Is NuVasive, Inc.'s (NASDAQ:NUVA) ROE Of 4.7% Concerning?
Simply Wall St. via Yahoo Finance
2 May 2023
|
|
Top Research Reports for American Express, Enbridge & Micron Technology
Zacks via Yahoo Finance
28 Apr 2023
|
|
Local medical tech company part of $3.1B merger deal
Dayton Daily News
28 Apr 2023
|
|
New Strong Buy Stocks for April 26th
Zacks via Yahoo Finance
26 Apr 2023
|
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 52.45M |
| Revenue | $1.23B |
|---|---|
| EBITDA | $201.06M |
| EBIT | $60.92M |
| Net Income | $28.45M |
| Revenue Q/Q | 2.36% |
| Revenue Y/Y | 4.44% |
| P/E ratio | 0.00 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | 0.00 |
| Book/Share | 17.04 |
| Cash/Share | 1.57 |
| EPS | $0.54 |
|---|---|
| ROA | 1.31% |
| ROE | 3.28% |
| Debt/Equity | 1.56 |
|---|---|
| Net debt/EBITDA | 5.54 |
| Current ratio | 1.25 |
| Quick ratio | 0.65 |